Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt S.A. announced that it will release its audited financial results for the year ending December 31, 2024, on April 30, 2025. An investor webinar, hosted by CEO Lyn Rees and CFO Steve Gibson, will be held on the same day to discuss the results, providing an opportunity for existing and potential investors to engage with the company’s leadership. This announcement is significant as it offers stakeholders insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor relations.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, focusing primarily on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation to deliver comprehensive solutions across sectors such as human health, animal health, and environmental. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, and has a commercial presence in over 65 countries.
YTD Price Performance: -11.61%
Average Trading Volume: 150
Technical Sentiment Signal: Buy
Current Market Cap: $39.28M
See more data about ALNOV stock on TipRanks’ Stock Analysis page.